Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer

Acta Oncologica

Volumn 37, Issue 7-8, 1998, Pages 651-659

  Hoffman, Katarina ^a,b   Glimelius, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; PREDNISOLONE;

ADULT; ALGORITHM; ARTICLE; BILE DUCT CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DIGESTIVE SYSTEM CANCER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; PALLIATIVE THERAPY; PANCREAS CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL ANALYSIS; WELLBEING;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; BODY WEIGHT; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PALLIATIVE CARE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS;

EID: 0032438345     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698429991     Document Type: Article

References (25)

1. 1. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Sequential methotrexate, 5-fluorouracil leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 1989; 7: 1437-46.
2. 2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-41.
3. 3. Glimelius B, Hoffman K, Påhlman L, et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide antigen specific (TPS) measurements. Acta Oncol 1996; 35: 141-8.
4. 4. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
5. 5. Hunt SM. The problem of quality of life. Qual Life Res 1997; 6: 205-12.
6. 6. Hopwood P, Stephens RJ, Machin D. For the MRC Lung Cancer Working Party. Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 1994; 3: 339-52.
7. 7. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. On behalf of the MRC Cancer Trials Office. Quality of life assessment in clinical trials-guidelines and a checklist for protocol writers: the UK Medical Research Council Experience. Eur J Cancer 1997; 33: 20-8.
8. 8. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
9. 9. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
10. 10. Glimelius B, Hoffman K, Sjödén P-O, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
11. 11. Glimelius B, Ekström K, Hoffman K, et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-8.
12. 12. Wilke H, Preusser P, Stahl M, et al. Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991; 29: 83-4.
13. 13. Larsson PA, Carlsson G, Gustavsson B, et al. Different intravenous administration techniques for 5-fluorouracil-pharmacokinetic and pharmacodynamic effects. Acta Oncol 1996; 35: 207-13.
14. 14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
15. 15. Glimelius B, Hoffman K, Olafsdottir M, Påhlman L, Sjödén P, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma. A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25: 829-35.
16. 16. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjödén P-O, Wennberg A. Quality of life during chemotherapy in symptomatic patients with advanced colorectal cancer. Cancer 1994; 73: 556-62.
17. 17. Bergman B, Sullivan M, Sorenson S. Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC core quality of life questionnaire and comparison with the Sickness Impact Profile. Acta Oncol 1992; 31: 19-28.
18. 18. Fayers P, Aaronson N, Bjordal K, M Sullivan (eds). EORTC QLQ-C30 Scoring Manual. EORTC Quality of Life Study Group 1995; 1-25.
19. 19. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
20. 20. Orr S, Aisner J. Performance status assessment among oncology patients: a review. Cancer Treat Rep 1986; 70: 1423-9.
21. 21. Roila F, Lupattelli M, Sassi M, et al. Intra and interob-server variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 1991; 2: 437-9.
22. 22. Regan J, Yarnold J, Jones PW, Cooke NT. Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 1991; 64: 396-400.
23. 23. Adams SG, Britt DM, Godding PR, Khansur TI, Bulcourf BB. Relative contribution of the Karnofsky performance status scale in a multi-measure assessment of quality of life in cancer patients. Psycho-Oncology 1995; 4: 239-46.
24. 24. Sigurdadóttir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996; 35: 149-59.
25. 25. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996; 348: 1610-4.